{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:09:51Z","timestamp":1778764191537,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2026.02.012","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:22:34Z","timestamp":1774560154000},"page":"e1-e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S2","title":["Molecular Biomarkers for Predicting Treatment Response in Psoriatic Arthritis"],"prefix":"10.1016","volume":"51","author":[{"given":"Andre Lucas","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen M.","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2026.02.012_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41584-020-00507-9","article-title":"Applying precision medicine to unmet clinical needs in psoriatic disease","volume":"16","author":"Jadon","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2026.02.012_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2026.02.012_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkae074","article-title":"Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals","author":"Ribeiro","year":"2024","journal-title":"Rheumatology Advances in Practice"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12891-016-1319-x","article-title":"MATURA. Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study","volume":"17","author":"Kumar","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40271-021-00533-z","article-title":"Towards personalising the use of biologics in rheumatoid arthritis: a discrete choice experiment","volume":"15","author":"Vass","year":"2022","journal-title":"Patient"},{"issue":"8","key":"10.1016\/j.rdc.2026.02.012_bib13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/acr.24782","article-title":"Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment","volume":"74","author":"Sumpton","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.012_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib15","article-title":"Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response","volume":"8","author":"Curry","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.rdc.2026.02.012_bib16","article-title":"Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis","author":"Curry","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.012_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.012_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000646","article-title":"Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on ustekinumab","volume":"41","author":"De Keyser","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.012_bib19","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"van den Reek","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C\u221706:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.012_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: a case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.012_bib22","first-page":"1241","article-title":"The HLA-Cw\u221706 allele may predict the response to methotrexate (MTX) treatment in Chinese arthritis-free psoriasis patients","volume":"315","author":"Mao","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.012_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.humimm.2013.07.014","article-title":"Human leukocyte antigen alleles and susceptibility to psoriatic arthritis","volume":"74","author":"Chandran","year":"2013","journal-title":"Hum Immunol"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.012_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","article-title":"HLA-B27 and psoriatic disease: a modern view of an old relationship","volume":"55","author":"Queiro","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"Supplement_3","key":"10.1016\/j.rdc.2026.02.012_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez107.027","article-title":"211 is HLA-B27 a predictor of treatment response to biologics in psoriatic arthritis?","volume":"58","author":"David","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.012_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40291-016-0198-z","article-title":"A pharmacogenetic study of psoriasis risk variants in a Greek population and prediction of responses to Anti-TNF-\u03b1 and Anti-IL-12\/23 agents","volume":"20","author":"Masouri","year":"2016","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.012_bib27","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/jdv.15431","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Ovejero-Benito","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.14461","article-title":"Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis","volume":"175","author":"Coto-Segura","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.012_bib29","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/ced\/llae128","article-title":"ERAP1 and ERAP2 gene variants as potential clinical biomarkers of anti-interleukin-17A response in psoriasis vulgaris","volume":"49","author":"Kronborg","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.012_bib30","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ajhg.2023.08.010","article-title":"Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background","volume":"110","author":"Zhang","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis","volume":"19","author":"Ovejero-Benito","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.012_bib32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs-2017-0014","article-title":"Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis","volume":"18","author":"Ovejero-Benito","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/tpj.2016.64","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Prieto-P\u00e9rez","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.rdc.2026.02.012_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112239","article-title":"Study of lncRNAs expression profile in the response to biological drugs in psoriatic arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy","volume":"134","author":"De Benedittis","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.rdc.2026.02.012_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1245876","article-title":"DNA methylation patterns in CD4+ T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis","volume":"14","author":"Natoli","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2026.02.012_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.746145","article-title":"DNA methylation patterns in CD8+ T cells discern psoriasis from psoriatic arthritis and correlate with cutaneous disease activity","volume":"9","author":"Charras","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.rdc.2026.02.012_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964274","article-title":"Combined - whole blood and skin fibroblasts- transcriptomic analysis in psoriatic arthritis reveals molecular signatures of activity, resistance and early response to treatment","volume":"13","author":"Grivas","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78866-2","article-title":"Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis","volume":"10","author":"Rahmati","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.rdc.2026.02.012_bib39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2014.00578","article-title":"MicroRNA-146a: a dominant, negative regulator of the innate immune response","volume":"5","author":"Saba","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/jcm8010110","article-title":"MiR-146a-5p expression in peripheral CD14+ monocytes from patients with psoriatic arthritis induces osteoclast activation, bone resorption, and correlates with clinical response","volume":"8","author":"Lin","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.012_bib41","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/cells9071603","article-title":"Expression of miR-135b in psoriatic skin and its association with disease improvement","volume":"9","author":"Chicharro","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.rdc.2026.02.012_bib42","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3899\/jrheum.190602","article-title":"Serum MicroRNA signature as a diagnostic and therapeutic marker in patients with psoriatic arthritis","volume":"47","author":"Wade","year":"2020","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.012_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/ard.2006.060079","article-title":"Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate","volume":"66","author":"Gratac\u00f3s","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.012_bib44","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/acr.22257","article-title":"Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis","volume":"66","author":"Au","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib45","first-page":"23","article-title":"Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment","volume":"30","author":"Chimenti","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib46","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.rdc.2026.02.012_bib47","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3390\/jcm10132834","article-title":"In patients with early peripheral psoriatic arthritis baseline C-Reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts\/bDMARDs. A retrospective analysis","volume":"10","author":"Sakellariou","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.012_bib48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","article-title":"Phase 2 trial of deucravacitinib in psoriatic arthritis: biomarkers associated with disease activity, pharmacodynamics, and clinical responses","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2026.02.012_bib49","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s10067-024-07193-y","article-title":"Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis","volume":"43","author":"K\u00fcnzler","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.012_bib50","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.3390\/ijms24076343","article-title":"Cytokine signatures in psoriatic arthritis patients indicate different phenotypic traits comparing responders and non-responders of IL-17A and TNF\u03b1 inhibitors","volume":"24","author":"Skougaard","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.012_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003042","article-title":"Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis","volume":"9","author":"Cardner","year":"2023","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.012_bib52","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/art.40921","article-title":"Responsiveness of serum C-Reactive protein, Interleukin-17A, and Interleukin-17F levels to ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials","volume":"71","author":"Siebert","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.012_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2026.02.012_bib54","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2024-0396","article-title":"Candidate biomarkers for response to treatment in psoriatic disease","author":"Offenheim","year":"2024","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.012_bib56","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.012_bib57","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/1346-8138.15278","article-title":"Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab","volume":"47","author":"Morita","year":"2020","journal-title":"J Dermatol"},{"issue":"2\u20133","key":"10.1016\/j.rdc.2026.02.012_bib58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475809","article-title":"Serum human Beta-Defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients","volume":"233","author":"Jin","year":"2017","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.012_bib59","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-019-1898-7","article-title":"Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor\/anti-citrulline antibody-negative rheumatoid arthritis","volume":"21","author":"Alivernini","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/ar3228","article-title":"Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study","volume":"13","author":"Pontifex","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.012_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/prca.201500051","article-title":"A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-\u03b1 treatment of psoriatic arthritis","volume":"10","author":"Collins","year":"2016","journal-title":"Proteomics Clin Appl"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.42288","article-title":"Dysregulation of bile acids, lipids, and nucleotides in psoriatic arthritis revealed by unbiased profiling of serum metabolites","volume":"75","author":"Paine","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2026.02.012_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.12688\/f1000research.4709.1","article-title":"Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis","volume":"3","author":"Armstrong","year":"2014","journal-title":"F1000Res"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.012_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15059","article-title":"Biological agent exerts therapeutic effects by reversing abnormalities in amino acid metabolic pathways in psoriasis","volume":"33","author":"Miao","year":"2024","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.012_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-023-02079-7","article-title":"Classifying patients with psoriatic arthritis according to their disease activity status using serum metabolites and machine learning","volume":"20","author":"Koussiouris","year":"2024","journal-title":"Metabolomics"},{"issue":"20","key":"10.1016\/j.rdc.2026.02.012_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015299","article-title":"Identifying serum metabolomic markers associated with skin disease activity in patients with psoriatic arthritis","volume":"24","author":"Choksi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rdc.2026.02.012_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2023.05.010","article-title":"Pharmacologic treatment strategies in psoriatic arthritis","author":"Ayan","year":"2023","journal-title":"Clin Ther"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X26000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X26000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:30:11Z","timestamp":1778761811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X26000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X26000128"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2026.02.012","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Biomarkers for Predicting Treatment Response in Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2026.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}